Clinical trial · Interventional
RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC
Renal Functional Reserve Change of Precise Segmental Versus Complete Renal Arterial Clamping During Laparoscopic Partial Nephrectomy for Clinical T1 Renal Cell Carcinoma
NCT03259477CI-TRIAL-00044878unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Renal functional reserve may be better in patients with clinical T1 renal cell carcinoma(RCC) undergoing laparoscopic partial nephrectomy with precise segmental renal artery clamping than those with complete renal arterial clamping.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laparoscopic partial nephrectomy | Procedure | — | UNRESOLVED |
| precise segmental renal arterial clamping | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- precise segmental clamping
- description
- These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
- interventionNames
- Procedure: precise segmental renal arterial clamping
- Procedure: laparoscopic partial nephrectomy
- type
- ACTIVE_COMPARATOR
- label
- complete clamping
- description
- These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
- interventionNames
- Procedure: laparoscopic partial nephrectomy
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * 1.Age ≥18 2.Estimated GFR \>30 mL/min/1.73m2 3.Anticipated intraoperative warm ischemic time ≤30 min 4.Subjects who signed informed consent forms Exclusion Criteria: 1. Allergy to iothalamate, shellfish or iodine 2. Use of metformin or amiodarone 3. intraoperative warm ischemic time \>30 min 4. Inability to maintain a stable regimen of medications which affect GFR for \> one week prior to participation (e.g. non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers) 5. Use of medications which directly affect elimination of creatinine (e.g. cimetidine and trimethoprim) 6. Acute exacerbation of asthma or chronic obstructive pulmonary disease within 3 months requiring hospitalization or oral steroid therapy 7. Inadequate intravenous access 8. Severe anemia (Hct \<21%) 9. Acute kidney injury (rise in creatinine to ≥1.5 times the previous baseline or by ≥ 0.3 mg/dL on most recent labs prior to enrollment) 10. History of contrast-induced nephropathy 11. Hyperthyroidism 12. Pheochromocytoma 13. Sickle cell disease 14. Urinary retention or incontinence 15. Status post organ transplant 16. Pregnancy or active breast feeding 17. Cognitive impairment with inability to give consent 18. Institutionalized status
References
Publications (0)
Data not yet available
No reference posted for this study.